Bristol-Myers Squibb Company reported second-quarter revenues of $12.3 billion for 2025, reflecting a 1% increase compared to the same period in 2024. The Growth Portfolio generated $6.6 billion in revenue, an 18% increase, while the Legacy Portfolio saw a 14% decline to $5.7 billion. The company's GAAP EPS was reported at $0.64, with non-GAAP EPS at $1.46, both figures impacted by a charge related to a strategic partnership with BioNTech. The company has raised its 2025 revenue guidance to between $46.5 billion and $47.5 billion, along with an updated non-GAAP EPS range of $6.35 to $6.65, which accounts for the aforementioned charge.
In addition to its financial results, Bristol-Myers Squibb announced several strategic partnerships aimed at enhancing its product pipeline. Notably, the company has entered into a co-development agreement with BioNTech for a bispecific antibody targeting solid tumors and licensed rights for a prostate cancer therapeutic to RayzeBio, a subsidiary of Bristol-Myers. The company is also creating a new biopharmaceutical entity focused on autoimmune diseases with Bain Capital. These initiatives suggest a focus on expanding their therapeutic offerings and addressing unmet medical needs, which may influence future performance.
linkJul 31, 2025 07:06:45
Bristol Myers Squibb Company has announced that Dr. Samit Hirawat, the Chief Medical Officer and Head of Development, will transition to an advisory role effective August 1, 2025, and will leave the company by November 1, 2025. In connection with his departure, Dr. Hirawat will receive severance benefits, pro-rated equity awards, and an annual incentive payout for 2025. The company has expressed gratitude for his contributions over the past six years, during which he played a key role in advancing the company’s drug development efforts.
Cristian Massacesi, M.D., will join Bristol Myers Squibb as the new Chief Medical Officer and Head of Development, effective August 1, 2025. Dr. Massacesi brings over 20 years of global biopharmaceutical experience, having previously served as Chief Medical Officer at AstraZeneca and Alexion. His extensive background includes overseeing numerous clinical studies and securing regulatory approvals. He will report directly to the CEO and is expected to lead the company’s product development across various therapeutic areas.
linkJul 25, 2025 16:43:19
Bristol Myers Squibb reported first quarter revenues of $11.2 billion for 2025, a decrease of 6% from the previous year. The company's Growth Portfolio showed a revenue increase of 16%, driven by products such as Opdivo, Breyanzi, Reblozyl, and Camzyos, while the Legacy Portfolio saw a decline of 20% due to generic competition affecting key drugs. The GAAP earnings per share (EPS) was $1.20, with non-GAAP EPS reported at $1.80.
The company has raised its 2025 revenue guidance to a range of approximately $45.8 billion to $46.8 billion, reflecting strong performance in the Growth Portfolio and favorable foreign exchange impacts. Additionally, the non-GAAP EPS guidance has been increased to a range of $6.70 to $7.00. These adjustments are based on better-than-expected sales and a favorable outlook for royalties and interest income.
linkApr 24, 2025 07:11:41
Bristol Myers Squibb reported fourth quarter revenues of $12.3 billion, an 8% increase from the previous year, driven largely by a 21% rise in Growth Portfolio revenues. The company achieved significant clinical and regulatory milestones, including the U.S. approval of Cobenfy for schizophrenia treatment. Additionally, Bristol Myers Squibb is expanding its strategic initiative to save approximately $2 billion by the end of 2027, aiming for enhanced operational efficiency while supporting growth brands.
Conversely, the company faced challenges with a GAAP loss per share of $(4.41) for the full year, attributed to a significant non-tax deductible charge related to acquisitions. Non-GAAP earnings per share also decreased 85% year-over-year, reflecting the impact of acquired IPRD charges and licensing income. The Legacy Portfolio saw a decline in revenues due to the effects of generics on key products like Revlimid and Sprycel, which offset some of the growth from the newer offerings.
linkFeb 06, 2025 07:46:11
Bristol-Myers Squibb Company highlighted its advanced growth portfolio, which is expected to achieve double-digit sales growth and exceed 50% of revenues by 2025. The company has successfully integrated strategic acquisitions and made significant progress towards its $10 billion debt paydown commitment. The launch of key products, including Cobenfy for schizophrenia, has received positive feedback and is tracking ahead of expectations for Medicare and Medicaid coverage. The company is focused on delivering breakthrough medicines and maintaining a strong financial position as it enters 2025.
However, the company also faces challenges, including the inherent risks associated with clinical trials and regulatory approvals, as well as potential delays in product development and commercialization. There are concerns regarding the impact of new laws, market exclusivity rights, and the complexities of executing its business strategy. The company emphasizes the importance of disciplined execution and operational excellence to navigate these challenges while pursuing its growth objectives.
linkJan 13, 2025 10:20:34
Bristol Myers Squibb announced third quarter revenues of $11.9 billion, reflecting an 8% increase compared to the previous year, with notable growth in its Growth Portfolio, which reached $5.8 billion, an 18% increase. The company also achieved U.S. approval for Cobenfy, a new treatment for schizophrenia, and raised its 2024 revenue guidance, indicating positive momentum in its product portfolio and pipeline developments.
Conversely, the company reported a decline in earnings per share, with GAAP EPS falling to $0.60 from $0.93, and non-GAAP EPS decreasing to $1.80 from $2.00. The decrease in profitability was attributed to higher expenses from recent acquisitions, increased amortization of intangible assets, and a significant rise in the effective tax rate. Additionally, generic competition led to a decline in sales for Sprycel, impacting overall revenue growth.
linkOct 31, 2024 07:52:43
Bristol Myers Squibb's Q2 2024 revenues reached $12.2 billion, up 9%, driven by a strong growth portfolio. Non-GAAP earnings per share rose 18% to $2.07. The company received U.S. approval for Breyanzi in new lymphoma treatments and is advancing its pipeline. However, GAAP earnings per share fell 16% due to increased expenses and impairments. Despite international revenue challenges, the company remains optimistic about future growth and has raised its 2024 guidance.
linkJul 26, 2024 07:46:16
Bristol Myers Squibb appoints Michael R. McMullen, an experienced executive, to its Board of Directors, effective July 1, 2024. McMullen's successful track record in leading large businesses and delivering shareholder returns is expected to strengthen the company's growth profile and pipeline. With over 20 years of leadership experience, including transforming Agilent into a market leader, his global expertise is seen as valuable. The Board welcomes McMullen's contributions as the company aims to capitalize on future opportunities, expanding the Board to 11 members upon his appointment.
linkJun 18, 2024 16:23:00
Bristol Myers Squibb reported a 5% revenue increase in Q1 2024, reaching $11.9 billion. The company completed strategic transactions and obtained U.S. approval for key medications. They are executing a cost-saving initiative to reinvest in innovation. However, they reported a GAAP loss per share of $(5.89) due to one-time charges. Operating expenses increased, impacting gross margin. International revenues remained steady, but U.S. revenues grew by 7%. Overall, the company aims to enhance its long-term growth profile and efficiency while navigating financial fluctuations.
linkApr 25, 2024 07:47:51
Bristol Myers Squibb cautions stockholders against Tutanota's mini-tender offer, advising not to tender shares due to below-market price risk and offer conditions. The SEC warns investors about mini-tender offers, and BMS urges caution, encouraging market participants to review SEC guidance and obtain current market quotations for shares.
linkFeb 14, 2024 16:32:28